Quartel Adrian W
Known title: Chief Medical OfficerCIK: 0001910132
Associated companies
Transaction History
| ZVRA | ▲ Buy | Option Exercise | 11,333 | — | 1/30/2026 | View on chart |
| ZVRA | ▼ Sell | Open Market | 4,533 | $40K | 1/30/2026 | View on chart |
| ZVRA | ▲ Buy | Option Exercise | 11,333 | — | 1/30/2026 | View on chart |
| ZVRA | ▼ Sell | Open Market | 4,533 | $40K | 1/30/2026 | View on chart |
We use analytics to understand how market-wall is used. No personal data is sold.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Zevra Therapeutics Reports Cash Plus Deal Below Rival's Price
Zevra Therapeutics announced a cash-plus agreement for its drug, priced below the price offered by a rival company. The deal shows the company is willing to accept a lower price to secure a partnership. This could impact the company's valuation and competitive position in the market.
Zevra Therapeutics Reports Cash Plus Deal Below Rival's Price. Zevra Therapeutics announced a cash-plus agreement for its drug, priced below the price offered by a rival company. The deal shows the company is willing to accept a lower price to secure a partnership. This could impact the company's valuation and competitive position in the market.